Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? 2014

Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
Institute of Pharmaceutical Medicine/ECPM, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland, klazien.matter@unibas.ch.

BACKGROUND The European Quality of Life-5 Dimensions (EQ-5D) instrument combines questionnaire responses into a single utility estimate using country-specific value sets. Countries without a national value set are advised to select one based on geographic proximity. In the absence of a Swiss value set, we used foreign value sets to gain insights into their appropriateness for use with Swiss cancer patients. METHODS EQ-5D health states and visual analogue scale (VAS) ratings were collected in one German and three Swiss oncology trials. Utilities were calculated based on the United Kingdom (UK), German (GE), French (FR) and European Union (EU) value sets. Resulting differences and Pearson partial correlation coefficients with corresponding VAS ratings were assessed. RESULTS In total, 202 Swiss and 154 German patients undergoing cancer treatment completed at least two EQ-5D forms. The mean difference between GE-based and FR-, UK- or EU-based utilities was significantly larger than the differences between the latter. The absolute mean difference between utilities and VAS ratings was highest for GE-based utilities, for Swiss (0.170, 95 % confidence interval [CI] 0.146-0.194) and German patients (0.174, 95 % CI 0.145-0.202). The correlation between GE-based utilities and VAS ratings was the lowest (r = 0.36, 95 % CI 0.33-0.40); the highest was between FR-based utilities and VAS ratings (r = 0.43, 95 % CI 0.39-0.46). CONCLUSIONS For Switzerland, utility calculations based on the German or French value set would be an obvious choice. Our results suggest that the German value set may not be the most appropriate for use with Swiss cancer patients. The French and EU value sets may be relevant alternatives and improve international comparability.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D005260 Female Females
D005858 Germany A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. The capital is Berlin.
D006113 United Kingdom Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London. Great Britain,Isle of Man

Related Publications

Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
November 2017, PharmacoEconomics,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
January 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
April 2020, Journal of physiotherapy,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
April 2021, PharmacoEconomics,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
December 2022, PharmacoEconomics,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
November 2023, PharmacoEconomics,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
June 2018, PharmacoEconomics,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
July 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
April 2023, The European journal of health economics : HEPAC : health economics in prevention and care,
Klazien Matter-Walstra, and Dirk Klingbiel, and Thomas Szucs, and Bernhard C Pestalozzi, and Matthias Schwenkglenks
July 2020, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation,
Copied contents to your clipboard!